| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT07593092 Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors |
Recruitment opened |
| 2026-08-14 | NCT07593092 Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors |
Trial sites reduced: 9 -> 4 locations |
| 2026-07-25 | NCT06619990 Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis |
Trial sites expanded: 66 -> 90 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-07-20 | NCT07713485 Study of XmAb412 in Healthy Participants | Phase 1 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and… | Ovarian Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06619990 | Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis | Ulcerative Colitis (UC) | Recruiting |
| Phase 1 | |||
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Ovarian Cancer | Recruiting |
| NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT07230353 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With… | Rheumatoid Arthritis | Recruiting |
| NCT07284797 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants… | Healthy | Recruiting |
| NCT07713485 | Study of XmAb412 in Healthy Participants | Not Applicable - Healthy Adult Participants | Recruiting |
| NCT07593092 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | Ovarian Cancer | Recruiting |